Literature DB >> 4023903

Antiestrogenic therapy of meningiomas--a pilot study.

T M Markwalder, R W Seiler, D T Zava.   

Abstract

Six patients with inoperable, nonoperative, or recurrent meningiomas were treated with the antiestrogenic agent tamoxifen (Nolvadex) during an 8-12-month period. Computer tomographic, scintigraphic, and clinical evidence of an unspecific tumor response was only encountered in one patient after 4 months of therapy with tamoxifen. The 2-year results did not indicate a favorable response to antiestrogenic treatment. The significance of sex-steroid receptors and their possible prognostic value in endocrine therapy of meningiomas is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023903     DOI: 10.1016/0090-3019(85)90030-8

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  14 in total

Review 1.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

2.  Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.

Authors:  S M Grunberg; M H Weiss
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

Review 3.  Orbital meningiomas: surgery, radiotherapy, or hormones?

Authors:  G E Rose
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

Review 4.  Management of pediatric intracranial meningiomas: an analysis of 31 cases and review of literature.

Authors:  Kapu Ravindranath; M C Vasudevan; Anil Pande; Nigel Symss
Journal:  Childs Nerv Syst       Date:  2013-01-05       Impact factor: 1.475

Review 5.  Multimodality Therapy of Patients with Refractory Meningiomas.

Authors:  Haroon Ahmad; David Schiff
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

6.  Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression.

Authors:  Katariina Korhonen; Tiina Salminen; Jani Raitanen; Anssi Auvinen; Jorma Isola; Hannu Haapasalo
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

Review 7.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

8.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

Authors:  J W Goodwin; J Crowley; H J Eyre; B Stafford; K A Jaeckle; J J Townsend
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

9.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Authors:  Thomas J Kaley; Patrick Wen; David Schiff; Keith Ligon; Sam Haidar; Sasan Karimi; Andrew B Lassman; Craig P Nolan; Lisa M DeAngelis; Igor Gavrilovic; Andrew Norden; Jan Drappatz; Eudocia Quant Lee; Benjamin Purow; Scott R Plotkin; Tracy Batchelor; Lauren E Abrey; Antonio Omuro
Journal:  Neuro Oncol       Date:  2014-08-06       Impact factor: 12.300

10.  Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma.

Authors:  Dustin M Dalgorf; Corwyn Rowsell; Juan M Bilbao; Joseph M Chen
Journal:  Skull Base       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.